PRESS RELEASE published on 02/06/2026 at 11:43, 1 month 20 days ago The Supervisory Board of Sartorius AG proposes a dividend of 0.74 euros per preference share The Supervisory Board of Sartorius AG proposes a dividend of 0.74 euros per preference share for fiscal 2025, the same as in 2024, totaling 50.8 million euros. Dividend to be paid on March 31, 2026 Annual General Meeting Dividend Proposal Sartorius AG Preference Share 0.74 Euros
BRIEF published on 02/03/2026 at 07:05, 1 month 23 days ago Sartorius annonce une forte croissance et des perspectives positives pour 2026 Stratégie D'investissement Solutions De Bioprocédés Résultats Financiers 2025 Perspectives Pour 2026 Croissance De Sartorius
BRIEF published on 02/03/2026 at 07:05, 1 month 23 days ago Sartorius Reports Strong Growth and Positive Outlook for 2026 Investment Strategy Bioprocess Solutions 2026 Outlook Financial Results 2025 Sartorius Growth
PRESS RELEASE published on 02/03/2026 at 07:00, 1 month 23 days ago Sartorius achieves considerable profitable growth in 2025 and maintains positive outlook Sartorius achieves considerable profitable growth in 2025 with a 7.6% increase in sales revenue to around 3.5 billion euros. Positive outlook maintained for 2026 Sartorius Profitable Growth Sales Revenue Positive Outlook 2026
BRIEF published on 01/14/2026 at 11:39, 2 months 12 days ago Sartorius élargit sa gamme de produits bio-circulaires pour améliorer la durabilité des bioprocédés Sartorius Durabilité ISCC Plus Bioprocédés Bio-circulaire
BRIEF published on 01/14/2026 at 11:39, 2 months 12 days ago Sartorius Expands Bio-Circular Product Range to Enhance Bioprocess Sustainability Sustainability Sartorius ISCC Plus Bioprocesses Bio-circular
PRESS RELEASE published on 01/14/2026 at 11:34, 2 months 12 days ago Sartorius expands bio-circular product offering for more sustainable bioprocesses Sartorius expands bio-circular product offering to support more sustainable bioprocesses by using ISCC Plus-certified materials, reducing dependence on fossil-based plastics Sustainability Sartorius ISCC Plus Bioprocesses Bio-circular
BRIEF published on 10/16/2025 at 07:05, 5 months 10 days ago Sartorius Projects Positive Growth After Strong Nine Months Sartorius Sales Revenue EBITDA Growth Pharmaceutical Market Bioprocess Solutions
BRIEF published on 10/16/2025 at 07:05, 5 months 10 days ago Sartorius prévoit une croissance positive après neuf mois solides Chiffre D'affaires Sartorius Marché Pharmaceutique Croissance De L'EBITDA Solutions De Bioprocédés
PRESS RELEASE published on 10/16/2025 at 07:00, 5 months 10 days ago Sartorius sharpens guidance after significantly profitable sales revenue growth in the first nine months Sartorius sharpens guidance after significantly profitable sales revenue growth in the first nine months of 2025. Group sales revenue up 7.5% with double-digit increase in EBITDA. Management specifies full-year guidance for the Group and divisions EBITDA Sartorius Profitable Growth Sales Revenue Full-year Guidance
Published on 03/26/2026 at 16:20, 4 hours 18 minutes ago ACCESS Newswire Upgrades the ACCESS Platform to Include Social Monitoring to Track Brand Conversations Across Major Social Platforms
Published on 03/26/2026 at 13:00, 7 hours 38 minutes ago Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 13:00, 7 hours 38 minutes ago GameSquare's Stream Hatchet Launches Creator Communities to Manage the Full Creator Marketing Lifecycle
Published on 03/26/2026 at 12:59, 7 hours 39 minutes ago Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance
Published on 03/26/2026 at 19:20, 1 hour 18 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 1 hour 29 minutes ago 2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 1 hour 29 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 2 hours 21 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 2 hours 21 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 2 hours 38 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 2 hours 38 minutes ago LABORATOIRES EUROMEDIS - Fin du contrat de liquidité